The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
Open accessAbstract
The World Health Organization (WHO) recommends that countries implement pharmacovigilance and collect information on active drug safety monitoring (aDSM) and management of adverse events. The aim of this prospective study was to evaluate the frequency and severity of adverse events to anti-tuberculosis (TB) drugs in a cohort of consecutive TB patients treated with new (i.e.bedaquiline, delamanid) and repurposed (i.e.clofazimine, linezolid) drugs, based on the WHO aDSM project. Adverse events were collected prospectively after attribution to a specific drug together with demographic, bacteriological, radiological and clinical information at diagnosis and during therapy. This interim analysis included patients who completed or were still on treatment at time of data collection. Globally, 45 centres from 26 countries/regions reported 658 patients (68.7% male, 4.4% HIV co-infected) treated as follows: 87.7% with bedaquiline, 18.4% with delamanid (6.1% with both), 81.5% with linezolid and 32.4% with clofazimine. Overall, 504 adverse event episodes were reported: 447 (88.7%) were classified as minor (grade 1–2) and 57 (11.3%) as serious (grade 3–5). The majority of the 57 serious adverse events reported by 55 patients (51 out of 57, 89.5%) ultimately resolved. Among patients reporting serious adverse events, some drugs held responsible were discontinued: bedaquiline in 0.35% (two out of 577), delamanid in 0.8% (one out of 121), linezolid in 1.9% (10 out of 536) and clofazimine in 1.4% (three out of 213) of patients. Serious adverse events were reported in 6.9% (nine out of 131) of patients treated with amikacin, 0.4% (one out of 221) with ethionamide/prothionamide, 2.8% (15 out of 536) with linezolid and 1.8% (eight out of 498) with cycloserine/terizidone. The aDSM study provided valuable information, but implementation needs scaling-up to support patient-centred care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914 · cited 3×
“4%) out of 653 patients (3 unknown status) with median (IQR) CD4 cell counts of 94 (30-212) cells/mm 3 .”
BackgroundMethod
Cited by
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases
Tadolini, M., Codecasa, L. R., García-García, J.-M., Blanc, F.-X., Borisov, S., Alffenaar, J.-W., Andréjak, C., Bachez, P., Bart, P.-A., Belilovski, E., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01398-2020 · Cited by 398
Self-citationMirzayev, F., Viney, K., Linh, N. N., Gonzalez-Angulo, L., Gegia, M., Jaramillo, E., Zignol, M., & Kasaeva, T. (2021) · European Respiratory Journal · doi:10.1183/13993003.03300-2020 · Cited by 301
Lan, Z., Ahmad, N., Baghaei, P., Barkane, L., Benedetti, A., Brode, S. K., Brust, J. C. M., Campbell, J. R., Chang, V. W. L., Falzon, D., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30047-3 · Cited by 268
Self-citation
Metadata
- Authors
- Borisov, S., Danila, E., Maryandyshev, A., Dalcolmo, M., Miliauskas, S., Kuksa, L., Manga, S., Skrahina, A., Diktanas, S., Codecasa, L. R., Aleksa, A., Bruchfeld, J., Koleva, A., Piubello, A., Udwadia, Z. F., Akkerman, O. W., Belilovski, E., Bernal, E., Boeree, M. J., Cadiñanos Loidi, J., Cai, Q., Cebrian Gallardo, J. J., Dara, M., Davidavičienė, E., Forsman, L. D., De Los Rios, J., Denholm, J., Drakšienė, J., Duarte, R., Elamin, S. E., Escobar Salinas, N., Ferrarese, M., Filippov, A., Garcia, A., García-García, J.-M., Gaudiesiute, I., Gavazova, B., Gayoso, R., Gomez Rosso, R., Gruslys, V., Gualano, G., Hoefsloot, W., Jonsson, J., Khimova, E., Kunst, H., Laniado-Laborín, R., Li, Y., Magis-Escurra, C., Manfrin, V., Marchese, V., Martínez Robles, E., Matteelli, A., Mazza-Stalder, J., Moschos, C., Muñoz-Torrico, M., Mustafa Hamdan, H., Nakčerienė, B., Nicod, L., Nieto Marcos, M., Palmero, D. J., Palmieri, F., Papavasileiou, A., Payen, M.-C., Pontarelli, A., Quirós, S., Rendon, A., Saderi, L., Šmite, A., Solovic, I., Souleymane, M. B., Tadolini, M., van den Boom, M., Vescovo, M., Viggiani, P., Yedilbayev, A., Zablockis, R., Zhurkin, D., Zignol, M., Visca, D., Spanevello, A., Caminero, J. A., Alffenaar, J.-W., Tiberi, S., Centis, R., D'Ambrosio, L., Pontali, E., Sotgiu, G., & Migliori, G. B.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2019-10-10
- Volume
- 54
- Issue
- 6
- Pages
- 1901522
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2979539159
- Cited by
- 178
- References
- 1
- FWCI
- 18.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. https://app.cochat.ai/papers/10.1183/13993003.01522-2019
- The paper
- Borisov, S., Danila, E., Maryandyshev, A., Dalcolmo, M., Miliauskas, S., Kuksa, L., Manga, S., Skrahina, A., Diktanas, S., Codecasa, L. R., Aleksa, A., Bruchfeld, J., Koleva, A., Piubello, A., Udwadia, Z. F., Akkerman, O. W., Belilovski, E., Bernal, E., Boeree, M. J., . . . Migliori, G. B. (2019). Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. European Respiratory Journal. https://doi.org/10.1183/13993003.01522-2019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.